Cost of cardiac stents cut by 75%: Dept of pharmaceuticals prohibits manufacturers from withdrawing products

After the National Pharmaceutical Pricing Authority (NPPA), India's drug pricing regulator, reduced the price of cardiac stents by almost 75 percent, the government now has prohibited stent-makers from withdrawing their products from the market for the next six months.

FP Staff April 25, 2017 13:48:42 IST
Cost of cardiac stents cut by 75%: Dept of pharmaceuticals prohibits manufacturers from withdrawing products

After the National Pharmaceutical Pricing Authority (NPPA), India's drug pricing regulator, reduced the price of cardiac stents by almost 75 percent, the government now has prohibited stent-makers from withdrawing their products from the market for the next six months.

Cost of cardiac stents cut by 75 Dept of pharmaceuticals prohibits manufacturers from withdrawing products

Representational image. Reuters

Cardiac stents are wire mesh tubes — extremely small ones — used to unclog coronary arteries and help in preventing heart attacks. The NPPA proposed that the maximum prices of the drug-eluting stents (DES) be fixed between Rs 21,881 and Rs 67,272, according to an Economic Times report.

According to The Times of India, the government has "invoked special powers under the law directing companies to maintain production, import and supply of coronary stents to avoid any shortage." After the pricing regulation was announced, big pharma companies like Abott, Medtronic and Boston Scientific Corporation are looking to recall their products.

According to another Economic Times report, an Abbott spokesperson is quoted as saying, "Following the NPPA price ceiling decision in February 2017 and over the past two months, we have examined and re-examined whether there is a sustainable way to make available in India two of Abbott's latest stent technologies — the Alpine drug eluting stent and the Absorb dissolving stent — considering their higher manufacturing costs and other associated costs."

According to another Economic Times report, the manufacturers and importers have been directed to submit a weekly report on the number of coronary stents being produced and distributed in India, including weekly production plans to NPPA and the Drugs Controller General of India (DCGI).

The Times of India has also reported that there a few stent-makers who are finding novel ways to circumvent the price caps including special offers like "buy 10 and get 3 free". Addressing this problem, the NPPA has issued a memorandum asking companies to abide by its rules, warning that failure to do so would mean that the companies would be prosecuted under the Essential Commodities Act.

Updated Date:

also read

Why antibodies detected in a survey is not a guarantee of herd immunity against fresh infection
India

Why antibodies detected in a survey is not a guarantee of herd immunity against fresh infection

Compared to the uncertain strength and duration of immunity conferred by natural infection, the immunity conferred by the vaccine is stronger and will probably last longer

COVID-19 Delta variant expected to become dominant strain in coming months, says WHO
World

COVID-19 Delta variant expected to become dominant strain in coming months, says WHO

The organisation said overall 3.4 million new COVID-19 cases were reported in the week to 18 July, which is a 12 percent increase from the week before

Goa follows Centre's footsteps, says no patient deaths due to oxygen shortage
India

Goa follows Centre's footsteps, says no patient deaths due to oxygen shortage

Earlier the Goa health minister had said on 11 May that 26 persons had died within 24 hours at the GMCH due to oxygen shortage.